A blog bringing you perspectives from the frontlines of the drug pricing debate.
It’s widely agreed that Medicare Part D is one of the most successful public-private partnerships, delivering affordability and…
Product hopping is a practice commonly used by pharmaceutical companies to extend the life of their patents, and…
President Trump has signed an Executive Order to eliminate drug rebates in Medicare Part D, after the Administration…
The Trump Administration recently announced an Executive Order to implement the “Rebate Rule” and eliminate rebates in Medicare…
Published in The Newnan Times-Herald As COVID-19 continues to impact the nation, Georgia’s Governor and state legislature are…
Anyone following the U.S. drug pricing debate knows that “drug prices” are complicated. Most brand-name prescription drugs sold…
Today, millions of Americans are staying home during the threat of COVID-19. Access to affordable prescription drugs remains…
Three months into 2020 and the prescription drug pricing crisis continues to grow; in January alone, drug manufacturers…
With the Iowa caucuses and New Hampshire primary taking the spotlight, national attention on the presidential race and…
Published in Morning Consult With the United States in a debate on high drug prices, solutions are being…
